NASDAQ · NVCR
Healthcare · Medical - Instruments & Supplies
$16.15
Up+$0.22 (+1.36%)
Updated Sep 16, 2026, 5:54 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NVCR closed at $16.15 after 20 trading sessions, down 6.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $16.13 | $16.66 | $15.96 | $16.15 | 914.85K |
| Sep 14, 2026 | $15.49 | $16.25 | $15.285 | $16.22 | 1.05M |
| Sep 11, 2026 | $15.50 | $16.00 | $15.35 | $15.51 | 1.13M |
| Sep 10, 2026 | $15.26 | $16.07 | $15.10 | $15.35 | 1.39M |
| Sep 9, 2026 | $16.56 | $16.645 | $15.60 | $15.63 | 996.52K |
| Sep 8, 2026 | $17.635 | $17.775 | $16.57 | $16.85 | 1.46M |
| Sep 4, 2026 | $17.53 | $18.015 | $17.47 | $17.94 | 732.17K |
| Sep 3, 2026 | $17.94 | $18.045 | $17.42 | $17.64 | 613.41K |
| Sep 2, 2026 | $17.88 | $18.59 | $17.50 | $17.83 | 1.32M |
| Sep 1, 2026 | $17.36 | $17.875 | $17.29 | $17.38 | 800.36K |
| Aug 31, 2026 | $17.55 | $17.97 | $17.39 | $17.65 | 914.82K |
| Aug 28, 2026 | $17.99 | $18.159 | $17.42 | $17.82 | 855.58K |
| Aug 27, 2026 | $17.92 | $18.21 | $17.48 | $17.99 | 763.44K |
| Aug 26, 2026 | $17.43 | $17.97 | $17.15 | $17.89 | 1.27M |
| Aug 25, 2026 | $16.975 | $17.64 | $16.92 | $17.62 | 902.96K |
| Aug 24, 2026 | $17.02 | $17.055 | $16.33 | $16.76 | 1.61M |
| Aug 21, 2026 | $17.75 | $17.825 | $17.01 | $17.10 | 1.4M |
| Aug 20, 2026 | $18.12 | $18.61 | $17.48 | $17.77 | 955.71K |
| Aug 19, 2026 | $17.40 | $18.34 | $17.38 | $18.20 | 4.84M |
| Aug 18, 2026 | $17.25 | $17.73 | $17.08 | $17.24 | 792.64K |
The latest Smart Investors Daily articles mentioning NVCR.
NVCR research
Company profile and research snapshot.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 24, 2026 | Wedbush | Neutral | — |
| Jul 23, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 13, 2026 | JP Morgan | Neutral | — |
| Jun 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 4, 2026 | Wells Fargo | Equal-Weight | — |
Generated Sep 16, 2026, 5:25 PM
NovoCure Limited shares gained 1.36% today as the company participated in the Morgan Stanley 24th Annual Global Healthcare Conference, providing investors with an opportunity to hear directly from management about the company's strategic direction and market outlook. While the conference presentation itself carries neutral sentiment, the stock's modest uptick suggests positive investor reception to the company's messaging and positioning within the healthcare sector.
Bottom line: NovoCure's modest 1.36% gain reflects steady investor interest following the Morgan Stanley conference appearance, though the neutral sentiment around the presentation suggests management maintained rather than exceeded expectations. Investors should monitor upcoming earnings reports and clinical pipeline developments for more substantial catalysts, while keeping watch on reimbursement trends and competitive dynamics in the oncology treatment space.
SeekingAlpha · Sep 14, 2026
NovoCure Limited (NVCR) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsFrank Leonard - CEO &...
Yahoo · Sep 7, 2026
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
Yahoo · Sep 2, 2026
BAAR, Switzerland, September 02, 2026--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events.
Yahoo · Aug 28, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVCR.
